| Literature DB >> 18793431 |
Andrée M Vandermeeren1, Carmen Elena Gómez, Cristina Patiño, Elena Domingo-Gil, Susana Guerra, Jose Manuel González, Mariano Esteban.
Abstract
To identify the subcellular forms and biochemical events induced in human cells after HCV polyprotein expression, we have used a robust cell culture system based on vaccinia virus (VACV) that efficiently expresses in infected cells the structural and nonstructural proteins of HCV from genotype 1b (VT7-HCV7.9). As determined by confocal microscopy, HCV proteins expressed from VT7-HCV7.9 localize largely in a globular-like distribution pattern in the cytoplasm, with some proteins co-localizing with the endoplasmic reticulum (ER) and mitochondria. As examined by electron microscopy, HCV proteins induced formation of large electron-dense cytoplasmic structures derived from the ER and containing HCV proteins. In the course of HCV protein production, there is disruption of the Golgi apparatus, loss of spatial organization of the ER, appearance of some "virus-like" structures and swelling of mitochondria. Biochemical analysis demonstrate that HCV proteins bring about the activation of initiator and effector caspases followed by severe apoptosis and mitochondria dysfunction, hallmarks of HCV cell injury. Microarray analysis revealed that HCV polyprotein expression modulated transcription of genes associated with lipid metabolism, oxidative stress, apoptosis, and cellular proliferation. Our findings demonstrate the uniqueness of the VT7-HCV7.9 system to characterize morphological and biochemical events related to HCV pathogenesis.Entities:
Mesh:
Substances:
Year: 2008 PMID: 18793431 PMCID: PMC2553408 DOI: 10.1186/1743-422X-5-102
Source DB: PubMed Journal: Virol J ISSN: 1743-422X Impact factor: 4.099
Figure 1Compartmentalization of HCV proteins produced in HeLa cells infected with VT7-HCV. Subconfluent HeLa cells uninfected or infected at 5 PFU/cell with the recombinant VT7-HCV7.9 in the presence (+) or absence (-) of the inducer IPTG, were fixed at 24 h p.i, labelled with the corresponding primary antibody followed by the appropriate fluorescent secondary antibody and visualized by confocal microscopy. The antibodies or reagents used were Hα HCV to detect HCV proteins; Topro-3 to detect DNA; Rα Giantin to detect the Golgi complex (A); Rα Calnexine to detect the endoplasmatic reticulum (B) and Mitotracker Deep Red 633 to detect mitochondria (C). The co-localization is shown with a higher resolution in the white square.
Figure 2Alterations in the architecture of HeLa cells following expression of HCV proteins from VT7-HCV. HeLa cells uninfected or infected with the recombinant VT7-HCV7.9 in the presence or absence of the inducer IPTG, were chemically fixed at 16 h p.i and then processed for conventional embedding in an epoxy resin as described under Materials and Methods.A: Cellular architecture of uninfected HeLa cells. B: A general view of a cell infected with VT7-HCV7.9 in the absence of IPTG, showing the VACV forms IVs and IMVs. C and D: A general view of cells infected with VT7-HCV7.9 in the presence of IPTG, showing few IVs, large EDS, swollen mitochondria and vacuoles. E: High magnification of infected VT7-HCV7.9 cells in the presence of IPTG showing EDS with membranes, TS and swollen mitochondria with a protruding membrane. Note: Nucleus (N), mitochondria (m), Golgi apparatus (G), immature virus (IV), intracellular mature virus (IMV), tubular structures (TS), electron dense structures in membranous webs (EDS). Bar: 500 nm.
Figure 3Hepatocyte cell alterations following infection of HepG2 with VT7-HCV7.9. HepG2 cells uninfected or infected with the recombinant VT7-HCV7.9 in the presence or absence of the inducer IPTG were chemically fixed at 16 h p.i and then processed for conventional embedding in an epoxy resin.A: Cellular architecture of uninfected HepG2 cells. B: A general view of a cell infected with VT7-HCV7.9 in the absence of IPTG, showing the VACV forms IVs and IMVs.C, D and E: A general view of a cell infected with VT7-HCV7.9 in the presence of IPTG, showing large EDS surrounded by vacuoles and the presence of "virus-like particles" surrounded with membranes (*). Note: Vacuole (V) and electron dense structures in membranous webs (EDS). Bar: 200 nm.
Figure 4Immunogold electron microscopy analysis of the localization of HCV proteins in VT7-HCV. HeLa cells infected with VT7-HCV7.9 in the presence or absence of IPTG were chemically fixed, quickly frozen in liquid propane and then processed at low temperature in Lowicryl K4M resin. Immunogold labelling was performed with different antibodies. A: Cells infected with VT7-HCV7.9 in the absence of IPTG reacted with a serum from an HCV-infected patient.B: Cells infected with VT7-HCV7.9 in the presence of IPTG reacted with a serum from an HCV-infected patient C: Cells infected with VT7-HCV7.9 in the presence of IPTG reacted with a rabbit polyclonal anti-NS4B. D: Cells infected with VT7-HCV7.9 in the presence of IPTG reacted with a rabbit polyclonal anti-NS5A. E: Cells infected with VT7-HCV7.9 in the presence of IPTG reacted with a mouse monoclonal antibody anti-PDI. Note: Electron dense structures in membranous webs (EDS); mitochondria (m), immature virus (IV), intracellular mature virus (IMV), nucleus (N) and Vacuole (V). Bar: 250 nm.
Figure 5HCV polyprotein expression induced dysfunction of the mitochondria. A: HeLa cells uninfected or infected at 5 PFU/cell with the recombinant VT7-HCV7.9 in the presence or absence of IPTG were labelled in vivo at 24 h p.i with Mitotracker deep red (blue) to detect the mitochondria, with an anti-cytochrome c (red) antibody and with the serum from an HCV-infected patient to detect HCV proteins. Cells treated with staurosporine at 0.5 μM for 16 h were used as positive control. B: HeLa cells were either infected at 5 PFU/cell with the recombinant VT7-HCV7.9 in the presence or absence of IPTG, or treated with staurosporine at 0.5 μM for 16 h. At 48 h p.i, the mitochrondrial membrane potential (ΔΨm) was determined quantifying TMRE fluorescence. C: HeLa cells were either infected at 5 PFU/cell with the recombinant VT7-HCV7.9 in the absence or presence of IPTG or treated with staurosporine at 0.5 μM for 16 h. At 48 h p.i, the uninfected and infected cells were stained with dihydroethidium (2-HE) and subjected to flow cytometry. Note: STS: staurosporine.
Figure 6HCV proteins induced apoptosis in a caspase-dependent manner. A: Extent of apoptosis. HeLa cells were infected at 5 PFU/cell with the recombinant VT7-HCV7.9 in the presence or absence of IPTG. At 24 h p.i, uninfected and infected cells where fixed with an EtOH 70%-PBS solution, washed and stained with propidium iodide (PI) as explained in Material and Methods. The cell cycle was measure by flow cytometry. Cells treated with staurosporine at 0.5 μM for 16 h were used as positive control. B: Activation of effector caspases. HeLa cells were infected at 5 PFU/cell with the recombinant VT7-HCV7.9 in the presence (+) or absence (-) of IPTG individually or in combination with a general caspase inhibitor, zVAD-fmk at 50 μM. Cell lysates from uninfected and infected cells were collected at 48 h p.i and separated on a 12% SDS-PAGE for immunoblot analysis using an antibody that recognizes full-length (116 kDa) and cleavage-PARP (89 kDa) (left panel) or used for the quantification of the apoptotic levels by ELISA (right panel). C: Caspase-8 activation. HeLa cells were infected at 5 PFU/cell with the recombinant VT7-HCV7.9 individually or in combination with a caspase-8 inhibitor, zIEDT-fmk at 50 μM, in the presence (+) or absence (-) of IPTG. Uninfected and infected cell lysates were collected at 48 h p.i. and separated on a 12% SDS-PAGE for immunoblot analysis using an antibody that recognizes procaspase- (57 kDa) and active-caspase-8 (43 kDa) (left panel) or used for the quantification of the apoptotic levels by ELISA (right panel). D: Caspase-9 activation. HeLa cells were infected at 5 PFU/cell with the recombinant VT7-HCV7.9 individually in the presence (+) or absence (-) of IPTG or in combination with a caspase-9 inhibitor, zLEHD-fmk at 50 μM. Uninfected and infected cell lysates were collected at 48 h p.i and separated on a 12% SDS-PAGE for immunoblot analysis using an antibody that recognizes the active-caspase 9 (37 kDa) (left panel) or used for the quantification of the apoptotic levels by ELISA (right panel). Cells infected with the inducible VV-PKR were used as positive control.
Confirmation of microarray data by real time RT-PCR
| 2.65 | 1.39 | 2.07 | 2.28 | |
| 3.67 | 8.45 | 3.82 | 8.65 | |
| 5.67 | 7.49 | 8.16 | 10.1 | |
Microarray analysis revealed characteristic changes in gene expression profiling of HeLa cells during HCV protein expression from VT7-HCV7.9 (6 h p.i)
| RAD21 homolog (S. pombe) | RAD21 | ||
| Protein phosphatase 2 (formerly 2A), catalytic subunit, alpha isoform | PPP2CA | ||
| Hepatocellular carcinoma-associated antigen 66 | HCA66 | ||
| Glucose regulated protein, 58 kD | PDIA3 | ||
| Insulin-like growth factor 1 receptor | IGF1R | ||
| Sphingosine kinase type 2 isoform | SPHK2 | ||
| ATP synthase, H+ transporting, mitochondrial F1 complex | ATP5C1 | ||
| ATP synthase, H+ transporting, mitochondrial F1 complex, O subunit | ATP5O | ||
| Complement component 1, q subcomponent binding protein | C1QBP | ||
| NADH dehydrogenase (ubiquinone) 1 beta subcomplex, 9 (22 kD, B22) | NDUFB9 | ||
| Voltage-dependent anion channel 1 | VDAC1 | ||
| Surfeit 1 | SURF1 | ||
| Solute carrier family 25, member 10 | SLC25A10 | ||
| DnaJ (Hsp40) homolog, subfamily C, member 10 | DNAJC10 | ||
| Glutathione peroxidase 4 (phospholipid hydroperoxidase) | GPX4 | ||
| Fatty acid binding protein 5 (psoriasis-associated) | FABP5 | ||
| Nuclear receptor subfamily 5, group A, member 2 | NR5A2 | ||
| Peroxiredoxin 1 | PRDX1 | ||
| StAR-related lipid transfer (START) domain containing 4 | STARD4 | ||
| Cytochrome P450, family 19, subfamily A, polypeptide 1 | CYP19A1 | ||
| Glutathione S-transferase M1 | GSTM1 | ||
| ATPase, class I, type 8B, member 4 | ATP8B4 | ||
| 24-dehydrocholesterol reductase | DHCR24 | ||
| Peripheral myelin protein 2 | PMP2 | ||
| Glucose-6-phosphate dehydrogenase | G6PD | ||
| Clathrin, light polypeptide (Lca) | CLTA | ||
| Centaurin, gamma 2 | CENTG2 | ||
| Adaptor-related protein complex 3, sigma 1 subunit | AP3S1 | ||
| Coatomer protein complex, subunit beta | COPB1 | ||
| USO1 homolog, vesicle docking protein (yeast) | USO1 | ||
| SEC24 related gene family, member B (S. cerevisiae) | SEC24B | ||
| Paralemmin | PALM | ||
| Adaptor-related protein complex 2, mu 1 subunit | AP2M1 | ||
| Lectin, mannose-binding 2-like | LMAN2L | ||
| Reticulon 4 | RTN4 | ||
| Histone cluster 1, H2am | HIST1H2AM | ||
| Histone cluster 1, H4h | HIST1H4H | ||
| Histone cluster 2, H4a | HIST2H4A | ||
| H2A histone family, member Z | H2AFZ | ||
| Histone cluster 1, H4d | HIST1H4D | ||
| H3 histone, family 3B (H3.3B) | H3F3B | ||
| CDC28 protein kinase regulatory subunit 2 | CKS2 | ||
| Karyopherin alpha 2 (RAG cohort 1, importin alpha 1) | KPNA2 | ||
| Nuclear receptor subfamily 5, group A, member 2 | NR5A2 | ||
| Interleukin 6 (interferon, beta 2) | IL6 | ||
| Chloride intracellular channel 1 | CLIC1 | ||
| Neuroepithelial cell transforming gene 1 | NET1 | ||
| Interleukin-1 receptor-associated kinase 1 | IRAK1 | ||
| CDC42 small effector 1 | CDC42SE1 | ||
| DEAD (Asp-Glu-Ala-Asp) box polypeptide 5 | DDX5 | ||
| TP53RK binding protein | TPRKB | ||
| T-complex 1 | TCP1 | ||
| Eukaryotic translation initiation factor 4E | EIF4E | ||
| Olfactomedin 1 | OLFM1 | ||
| Leucine zipper, down-regulated in cancer 1 | LDOC1 | ||
| HtrA serine peptidase 3 | HTRA3 |